此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

姑息性放射治疗后的间质光动力疗法治疗无法手术的恶性中央气道梗阻患者

2026年11月4日 更新者:Roswell Park Cancer Institute

无法手术的恶性中央气道梗阻患者姑息放疗后间质光动力治疗的 I/II 期研究

This phase I/II trial studies the side effects of interstitial photodynamic therapy following palliative radiotherapy and how well it works in treating patients with inoperable malignant central airway obstruction. Patients who have advanced stage cancer tumors in the lung can often have the breathing passages to the lung partially or completely blocked. These tumors could be due to lung cancer or other cancers (e.g., renal, breast, kidney, etc.) that spread to the lung. This blockage puts the patient at a higher risk for respiratory failure, post-obstructive pneumonia, and prolonged hospitalizations. Treatment for these patients may include bronchoscopic intervention (such as mechanical removal, stenting, laser cauterization, or ballooning), radiation therapy with and without chemotherapy. While palliative x-ray radiotherapy may help in shrinking the tumor, high dose curative radiotherapy that can ablate (a localized, nonsurgical destruction) the tumor also has high risk to cause significant toxicity, including bleeding, abnormal connections or passageways between organs or vessels and abnormal scar tissue that can also produce airway obstruction. Photodynamic therapy (PDT) is another possible treatment that can provide local control of the tumor. PDT consists of injecting a light sensitive drug (photosensitizer, PS) into the vein, waiting for the PS to accumulate in the tumor, and then activating it with a red laser light. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving interstitial photodynamic therapy following palliative radiotherapy may improve tumor response and survival without the serious side effects that are associated with the typical high dose curative x-ray radiotherapy alone in patients with malignant central airway obstruction.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To test the safety of our image-based treatment planning for image-guided interstitial photodynamic therapy (I PDT) with endobronchial ultrasound (EBUS) following standard of care palliative radiotherapy (p-XRT). (Phase I)

-To assess the efficacy of our image-based treatment planning for image-guided I-PDT following standard of care p-XRT. (Phase II)

SECONDARY OBJECTIVES:

  • To assess objective tumor response. (Phase I)
  • To evaluate changes in quality of life. (Phase I and II)
  • To measure changes in functional lung capacity. (Phase I and II)
  • To measure the relationship between the measured objective tumor response (at 12 +/- 2 weeks post I-PDT) and changes in therapeutic laser light transmission within the target tumor, as a future dosimetric marker for response. (Phase I and II)
  • To assess treatment effects on the immune contexture. (Phase I and II)
  • To monitor progression free survival. (Phase I and II)

OUTLINE: This is a phase I study, followed by a phase II.

PHASE I: Patients are assigned to 1 of 2 cohorts.

COHORT 1: Patients receive visudyne intravenously (IV) over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo computed tomography (CT) throughout the trial.

COHORT 2: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

PHASE II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-90 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

After completion of study treatment, patients are followed up at 30 days and 8, 12, and 24 weeks.

研究类型

介入性

注册 (估计的)

42

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • New York
      • Buffalo、New York、美国、14263
        • 招聘中
        • Roswell Park Cancer Institute
        • 接触:
        • 首席研究员:
          • Nathaniel Ivanick
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Abramson Cancer Center

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age >= 18 years of age
  • Eligibility checklist before registration requires review of case by the interventional pulmonologist/s and radiation oncologist/s to approve anatomic feasibility of an airway intervention and palliative radiotherapy
  • Patients with pathologic diagnosis of inoperable solid malignancy involving extrabronchial tumor growth that causes airway obstruction and not amenable to curative radiotherapy. All patients will have tumors requiring bronchoscopic intervention with endobronchial ultrasound (EBUS) at the time of I-PDT
  • Participants have at least one measurable lesion which is also the target lesion for Response Evaluation Criteria in Solid Tumors (RECIST) measurement
  • Patients amenable to receive standard of care palliative radiotherapy to the target tumor, as determined by the radiation oncologist/s
  • Amenable to high resolution chest computed tomography (CT) scan (with or without contrast due to contraindication) with 0.625-1.25 mm slice thickness and slice interval 0.5-1 mm
  • Tumor is accessible and amenable to I-PDT, as determined by the interventional pulmonologist/s
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 3
  • Platelets ≥ 100,000 cells/mm^3 (International System of Units [SI] units 100 x 10^9/L)
  • International normalized ratio (INR) < 1.5 and activated partial thromboplastin time (aPTT) < 1.5 x ULN. PTT or aPTT per institutional standards for participating external sites
  • Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for 3 months after receiving the study drug. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Pregnant or nursing female participants
  • Co-existing ophthalmic disease likely to require slit-lamp examination within the next 30 days following I-PDT treatment
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the I-PDT
  • CT imaging suggestive of target tumor invasion into a major blood vessel (typically proximal to segmental vessels)
  • Known hypersensitivity/allergy to porphyrin
  • Patients who are not cleared by the anesthesiologist to undergo an advanced bronchoscopy procedure under general anesthesia
  • Patients who have received 120 Gy total radiation dose delivered to a structure within 1 cm margin of tumor volume to be targeted by p-XRT and I-PDT
  • Patients diagnosed with porphyria
  • Patients with known allergy to eggs
  • Patients unwilling or unable to follow protocol requirements

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Phase I cohort 1 (I-PDT, EBUS)

Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 3 treatment sessions. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

Undergo CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)

Ancillary studies

Undergo blood and tissue sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Ancillary studies

其他名称:
  • 体能测试
  • 身体机能测试

Undergo EBUS

其他名称:
  • EBUS
  • 支气管内超声

Undergo I-PDT

其他名称:
  • 光动力疗法
  • 间质照明光动力疗法

Given IV

其他名称:
  • 维舒达
  • 苯并卟啉衍生物单酸环A
  • BPD-MA
实验性的:Phase I cohort 2 (I-PDT, EBUS, palliative radiation therapy)

Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

Undergo CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)

Ancillary studies

Undergo blood and tissue sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Ancillary studies

其他名称:
  • 体能测试
  • 身体机能测试

Undergo EBUS

其他名称:
  • EBUS
  • 支气管内超声

Undergo I-PDT

其他名称:
  • 光动力疗法
  • 间质照明光动力疗法

Given IV

其他名称:
  • 维舒达
  • 苯并卟啉衍生物单酸环A
  • BPD-MA

Undergo palliative radiation therapy

其他名称:
  • 姑息性放疗

Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.

其他名称:
  • 光纤耦合二极管激光器:ML7710-PDT
实验性的:Phase II (I-PDT, EBUS, palliative radiation therapy)

Phase II: Patients undergo SOC p-XRT over a single fraction. Patients receive visudyne IV over 10 minutes and then undergo I-PDT with EBUS 60-120 minutes after visudyne for up to 2 treatment sessions at least 12 weeks apart. Patients undergo blood and tissue sample collection on study. Patients also undergo CT throughout the trial.

Undergo CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)

Ancillary studies

Undergo blood and tissue sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集

Ancillary studies

其他名称:
  • 体能测试
  • 身体机能测试

Undergo EBUS

其他名称:
  • EBUS
  • 支气管内超声

Undergo I-PDT

其他名称:
  • 光动力疗法
  • 间质照明光动力疗法

Undergo palliative radiation therapy

其他名称:
  • 姑息性放疗

Delivering the therapeutic 689+/-3 nm laser light during I-PDT. Measuring light transmission.

其他名称:
  • 光纤耦合二极管激光器:ML7710-PDT

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of >= grade 3 adverse events (Phase I)
大体时间:Within 30 days post interstitial photodynamic therapy (I-PDT)

Will will be associated with treatment related adverse events .grade 3 (with attribution of 'possible', 'probable' or 'definite'. Will be assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).

Within 30 days post interstitial photodynamic therapy (I-PDT)
Overall tumor response (Phase II)
大体时间:At 12 weeks post I-PDT

Will be assessed by complete response (CR) or partial response (PR) defined by the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1) criteria.

At 12 weeks post I-PDT

次要结果测量

结果测量
措施说明
大体时间
Overall tumor response (Phase I)
大体时间:At 12 weeks post I-PDT

Will be assessed by CR or PR defined by the RECIST v 1.1 criteria.

At 12 weeks post I-PDT
Quality of life (Phase I and II)
大体时间:At study enrollment, immediately prior to p-XRT and I-PDT, and at 4 and 12 weeks

Will be monitored using the Functional Assessment of Cancer Therapy-Lung. This 36 item self-reported quality of life questionnaire measures responses across six domains: physical well-being, social/family well-being, relationship with doctor, emotional well-being, functional well-being, and additional concerns. This scale was chosen because multiple studies support its validity and use in clinical trials of lung cancer.

At study enrollment, immediately prior to p-XRT and I-PDT, and at 4 and 12 weeks
Functional lung capacity (Phase I and II)
大体时间:At study entry (baseline), 30 days and 12 weeks

Will be measured with the six-minute walk test.

At study entry (baseline), 30 days and 12 weeks
Change in the therapeutic laser light transmission (Phase I and II)
大体时间:During the I-PDT

Will be measured with our light dosimetry system.

During the I-PDT
Association between immune markers and tumor response (Phase I and II)
大体时间:Prior and 7-10 days after the I-PDT

will be measured with flow cytometry in fresh blood samples collected prior and 7-10 days after the I-PDT.

Prior and 7-10 days after the I-PDT
Progression free survival (Phase I and II)
大体时间:Time from date of study treatment to the time of first observed disease progression (RECIST 1.1 criteria) at the treated tumor site or, death due to any cause, assessed up to 5 years

Will be summarized using standard Kaplan-Meier methods.

Time from date of study treatment to the time of first observed disease progression (RECIST 1.1 criteria) at the treated tumor site or, death due to any cause, assessed up to 5 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Nathaniel Ivanick、Roswell Park Cancer Institute

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年10月1日

初级完成 (估计的)

2029年10月1日

研究完成 (估计的)

2029年10月1日

研究注册日期

首次提交

2024年2月27日

首先提交符合 QC 标准的

2024年3月5日

首次发布 (实际的)

2024年3月12日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • I-3901323
  • I-3901323 (其他标识符:Roswell Park Cancer Institute)
  • NCI-2024-01239 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • R01CA283547 (美国 NIH 拨款/合同)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅